We conclude that PACAP (along with other markers) may be a promising biomarker in the future to aid in the diagnosis of MM, assess prognosis, and potentially monitor the efficacy of clinical therapy. This evidence concerns the gene ADCYAP1 and Miyoshi myopathy.